VIRACTA THERAPEUTICS INC (VIRX) Stock Price, Quote, News and Overview
NASDAQ:VIRX - Nasdaq - US92765F1084 - Common Stock - Currency: USD
VIRX Quote, Performance and Key Statistics
VIRACTA THERAPEUTICS INC
NASDAQ:VIRX (2/3/2025, 8:01:34 PM)
After market: 0.071 -0.01 (-8.74%)0.0778
-0.07 (-48.65%)
The current stock price of VIRX is 0.0778 USD. In the past month the price decreased by -56.02%. In the past year, price decreased by -87.45%.
VIRX Latest News, Press Releases and Analysis
What's going on in today's after hours session
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Get insights into the top gainers and losers of Monday's after-hours session.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Top movers in Monday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Keep an eye on the top gainers and losers in Monday's session.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
VIRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About VIRX
Company Profile
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 26 full-time employees. The company went IPO on 2005-09-27. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The firm is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Company Info
VIRACTA THERAPEUTICS INC
2533 S Coast Hwy 101, Suite 210
Cardiff-by-the-Sea CALIFORNIA 94080 US
CEO: Parvinder Hyare
Employees: 26
Company Website: https://www.viracta.com/
Investor Relations: https://viracta.investorroom.com/governance-documents
Phone: 18584008470
VIRX FAQ
What is the stock price of VIRX?
The current stock price of VIRX is 0.0778 USD.
What is the symbol for VIRACTA THERAPEUTICS INC stock?
The exchange symbol of VIRACTA THERAPEUTICS INC is VIRX and it is listed on the Nasdaq exchange.
On which exchange is VIRX stock listed?
VIRX stock is listed on the Nasdaq exchange.
Is VIRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VIRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VIRX.
Does VIRX stock pay dividends?
VIRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of VIRX?
VIRX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.1).
What is the Short Interest ratio of VIRX stock?
The outstanding short interest for VIRX is 0.64% of its float.
VIRX Technical Analysis
VIRX Financial Highlights
Over the last trailing twelve months VIRX reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS decreased by 11.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VIRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to VIRX. The Buy consensus is the average rating of analysts ratings from 6 analysts.